USOO8455494B2 (12) United States Patent (10) Patent No.: US 8,455,494 B2 Kaufman (45) Date of Patent: *Jun. 4, 2013 (54) PREPARATIONS AND METHODS FOR 5,153,205 A 10, 1992 Lotti AMELORATING OR REDUCING 5, 182,102 A 1/1993 DeSantis, Jr. et al. 5,229,127 A 7/1993 McKinzie PRESBYOPA 5,352,698 A 10, 1994 Santini 5,360,801 A 11/1994 Laties et al. (75) Inventor: Herbert E. Kaufman, Sarasota, FL (US) 5,384.243 A 1/1995 Gutkind et al. 5,422,116 A 6/1995 Yen et al. (73) Assignee: HEK Development, LLC, Sarasota, FL 5,459,133. A 10/1995 Neufeld (US) 5,459,140 A 10, 1995 Grammer 5,474,783 A 12/1995 Miranda et al. (*) Notice: Subject to any disclaimer, the term of this SE A 6.3% Built al. patent is extended or adjusted under 35 5,599,836 A 2f1997 Santini U.S.C. 154(b) by 0 days. 5,624,962 A 4/1997 Takeuchi et al. 5,656,286 A 8/1997 Miranda et al. This patent is Subject to a terminal dis- 5,677,327 A 10/1997 Gilet al. claimer. 5,679,713 A 10/1997 Hahnenberger 5,686,100 A 11, 1997 W11e et al. 5,688,510 A 11/1997 Nakamichi et al. (21) Appl. No.: 13/605.302 5,704,369 A 1/1998 Scinto et al. 5,773,466 A 6/1998 Santini (22) Filed: Sep. 6, 2012 5,776,916 A 7/1998 Gramer O O 5,811,446 A 9, 1998 Thomas (65) Prior Publication Data (Continued) US 2012/0329805 A1 Dec. 27, 2012 FOREIGN PATENT DOCUMENTS O O WO WO 2004 108135 12, 2004 Related U.S. Application Data WO WO 2005.115.375 12/2005 (63) Continuation of application No. 12/973,479, filed on (Continued) Dec. 20, 2010, now Pat. No. 8,299,079, which is a OTHER PUBLICATIONS continuation-in-part of application No. 12/785,734, filed on May 24, 2010, now abandoned. Miostat (MiostatDocument, 2008).* Kesler et al. (J Cataract Refract Surg 2004 30, 1707-1710).* (60) Provisional application No. 61/180,521, filed on May Adrenergic Agonists (Chapter 17, http://www.coursewareobjects. 22, 2009, provisional application No. 61/291,206, com/objects/evolve/E2/book pages/lehne/images/Ch17 filed on Dec. 30, 2009. Adrenergic Agonists.pdf. (2011), pp. 150-162. Agarwal, Refractive Surgery Nightmares, vol. 301, (2007), pp. 1-4. Alpha 1 Blocker (http://en.wikipedia.org/wiki/Alpha-1 blocker, (51) Int. C. (2011), pp. 1-3. A6 IK3I/498 (2006.01) Kesler et al. (J Cataract Refract Surg, 20, 2004, 1707-1710). A6IP27/02 (2006.01) Minims (Minims Pilocarpine Eye Drops, product information, 1999, (52) U.S. C. p. 1-4). USPC ............................ 514/249; 514/642: 514/912 Shiuey et al., “Cardiovascular Effects of Commonly Used Field of Classification Search Ophthalmic Medications.” Clin. Cardiol., vol. 19, (1996), pp. 5-8. (58) Tornqvist, “Effect of Topical Carbachol on the Pupil and Refraction CPC ....... A61K 31/498; A61 K9/0048 in Young and Presbyopic Monkeys.” Investigative Ophthalmology, USPC .................................................. 514/642, 912 See application file for complete search history. vol. 5, No. 2, (1966), pp. 186-195. Primary Examiner — Sreeni Padmanabhan (56) References Cited Assistant Examiner — Uma Ramachandran U.S. PATENT DOCUMENTS (74) Attorney, Agent, or Firm — Brinks Hofer Gilson & Lione 4,001,388 A 1, 1977 Shel1 4,008,719 A 2f1977 Theeuwes et al. 4,014,334 A 3, 1977 Theeuwes et al. (57) ABSTRACT 4,014,335 A 3, 1977 Arnold This application relates to the use of one or more parasym 4,115,544. A 9, 1978 Shell 4,136,173 A 1/1979 Pramoda et al. pathomimetic drugs in combination with one or more alpha 4,136,177 A 1/1979 Lin et al. agonists to create optically beneficial miosis to, for example, 4,136,178 A 1/1979 Lin et al. temporarily treat presbyopia. The invention provides a phar 4,186,184 A 1, 1980 Zaffaroni maceutical preparation comprising atherapeutically effective 4,271,143 A 6, 1981 Schoenwald et al. amount of one or more parasympathomimetic drugs or cho 4,407,792 A 10, 1983 Schoenwald et al. 4.459,309 A 7, 1984 Chiou linesterase inhibitors, or a pharmaceutically acceptable salt 4.474,751 A 10, 1984 Haslam et al. thereof, in combination with one or more alpha agonists or 4,652,571 A 3/1987 Croom, Jr. et al. antagonists, or a pharmaceutically acceptable salt thereof. 4,661.509 A 4, 1987 Gordon et al. The invention further provides for a method for treating, 4,668,506 A 5, 1987 Bawa ameliorating or reducing presbyopia of a patient having an 4,713,244. A 12/1987 Bawa et al. 4,931,279 A 6, 1990 Bawa et al. eye, comprising administering to said eye a pharmaceutically 4,952.212 A 8, 1990 Booth et al. effective amount of the ophthalmic preparation. 5,010,056 A 4, 1991 Boghen et al. 5,084.281 A 1, 1992 Dillon 12 Claims, 2 Drawing Sheets US 8,455,494 B2 Page 2 U.S. PATENT DOCUMENTS 7.323,463 B2 1, 2008 Chang et al. 5,817,630 A 10/1998 Hofmann et al. 7,345,065 B2 3/2008 Gilet al. 7,371,534 B2 5/2008 Kauffman et al. 5,843,016 A 12/1998 Lugnani et al. 7,384,651 B2 6, 2008 Hille etal 5,843,979 A 12/1998 Wille et al. 7,439,241- w B2 10/2008 DeJovin et al. 5,858.410 A 1/1999 Muller et al. 7.494.983 B2 2/2009 Chen et all 5,858.996 A 1/1999 Tsao 7.528,163 B2 5 2009 Doherty et al. 5.5,861,431 A g1/1999 thingerHildebrand et al. 7.534,7057,560.100 B2 7/20095/2009 PinchasiRuckmicket etal all - K. 4 ille et al. 7,563,816 B2 7/2009 Doherty et al. 5.948,401 A 9, 1999 Donabedian et al. 7.572.776 B2 8, 2009 Yu et all 5,977,174. A 1 1/1999 Bradley et al. 776.15 (5 & 56 Slal 6,011,062 A 1/2000 Schneider et al. 7:557 (5 656, Ral 6,024,976 A 2/2000 Miranda et al. 7,642.258 B2 1/2010 R et al. 6,043,273 A 3/2000 Duhaylongsod 7,645.5ss B2 1/2010 Roos etal 6,060,454. A 5/2000 Duhaylongsod 7749.730I-1 B2 T/2010 B ryant et al. 6,066,675 A 5/2000 Wen et al. 2001/00470 12 A1 1 1/2001 DeSantis, Jr. 6,087.394 A 7/2000 Duhaylongsod 6,127.410 A 10/2000 Duhaylongsod 2002fO1973.00 A1 12/2002 Schultz et al. 6,164.282 A 12, 2000 G al 2003.0036535 A1 2/2003 Nolan 6.74534 B1 1, 2001 E. sal 2003/O125351 A1 7/2003 AZuma et al. 6.184250 B1 2/2001 E. tal 2004/0116524 A1 6/2004 Cohen et al. 6.194.415 Bi 2,200 W. f 2004/O137068 A1 7, 2004 Bhushan 6.242.442 B 6/2001 D e st al. 2004/0176408 A1 9, 2004 Horn 6.248,741 Bi 6/2001 WE 1 2004/0192647 A1 9/2004 Babizhayev 6.273,092 B 8,200 Sere a. 2004/022401.0 A1 11/2004 Hofland et al. 4 - 2004/O247681 A1 12, 2004 Ellis et al. 32.5 R 239; y stal 2005/0085508 A1 4/2005 Fukutomi et al. 6.294.563 B 9/2001 sal. 2005. O130906 A1 6, 2005 Matier et al. 6,313.55 B 11/2001 Sponse 2005, 0131025 A1 6, 2005 Matier et al. - K - 2005/0239871 A1 10/2005 Hellberg et al. E. E. 58 C.E. 2005, O250788 A1 11/2005 Tu et al. 640,544 B 6/2002 Gwon et al. 2006/0166879 A1 7/2006 Bhushan et al. 6,414,018 B1 7/2002 Duhaylongsod 2006/0172972 A1 8, 2006 Bhushan et al. 6.420,407 B1 7, 2002 Horn 2006/0177430 A1 8, 2006 Bhushan et al. 6,441,047 B2 8/2002 DeSantis, Jr. 2006/0194874 A1 8/2006 Menotti et al. 6,458,376 B1 10/2002 Meadows 2006/0233859 A1 10/2006 Whitcup et al. 6,511,817 B1 1/2003 Lynch et al. 2006/0233860 A1 10/2006 Chang et al. 6,528,520 B2 3/2003 Clemens 2006/0257452 A1 1 1/2006 Hughes et al. 6,544,927 B2 4/2003 Burns 2006, O292189 A1 12/2006 Xia et al. 6,551,584 B2 4/2003 Bandyopadhyay et al. 2007.0053964 A1 3, 2007 ISOwaki et al. 6,562.563 B1 5/2003 Murphy et al. 2007/0059274 A1 3/2007 Asgharian et al. 6,610,713 B2 8/2003 Tracey 2007/O1224.50 A1 5, 2007 Osio Sancho 6,649,625 B2 11/2003 AZuma et al. 2007/0129441 A1 6, 2007 Koulen gi R 13. My et al 1 2007/0275098 A1 11/2007 Banks 6,711,436w - B1 3/2004 DuhaylongsodZU ca. 2008/0085263 A1 4/2008 Thuresson et al. 6,800,668 B1 10, 2004 Odidi et al. 2008/0107738 A1 5/2008 Phillips et al. 6,806,285 B1 10/2004 May et al. 2008/01 12922 A1 5/2008 Hughes et al. 6,814,976 B1 11/2004 Hille et al. 2008/O131484 A1 6/2008 Robinson et al. 6,846,831 B2 1/2005 Clemens 2008/030O277 A1 12/2008 Fetz et al.